LL-37 Peptide in Chitosan Hydrogel Accelerates Pressure Ulcer Healing in Mice
Chitosan hydrogel encapsulated with LL-37 cathelicidin peptide significantly reduced pressure ulcer area and promoted angiogenesis through HIF-1α and VEGF-A upregulation in a mouse model.
Quick Facts
What This Study Found
LL-37/chitosan hydrogel significantly reduced pressure ulcer area to 48.12% by day 15, with increased epithelial thickness, capillary density, and upregulated HIF-1α and VEGF-A expression at both mRNA and protein levels.
Key Numbers
2.5% chitosan hydrogel; no cytotoxicity; enhanced TNF-alpha; faster wound healing in mice.
How They Did This
Mouse pressure ulcer model using magnets on 12/12h schedule for 21 days. Groups: LL-37/CS hydrogel (20 μg LL-37), naked LL-37 (20 μg), hydrogel alone, no treatment (n=6/group). Measured ulcer area, histology, cytotoxicity, TNF-α release, antibacterial activity, and angiogenesis markers.
Why This Research Matters
Pressure ulcers affect millions of bedridden patients and are difficult to treat. A biocompatible, antibacterial, wound-healing hydrogel combining LL-37's antimicrobial and regenerative properties with sustained delivery could transform wound care.
The Bigger Picture
The combination of antimicrobial peptides with biocompatible delivery systems represents a convergence of infection control and tissue regeneration. LL-37/chitosan hydrogel addresses both the infection risk and poor healing that make pressure ulcers so difficult to manage.
What This Study Doesn't Tell Us
Mouse model with relatively small group sizes (n=6). Mouse skin heals differently than human skin. The magnet-based pressure ulcer model may not fully replicate clinical pressure ulcer pathophysiology. Long-term healing outcomes beyond day 21 not assessed.
Questions This Raises
- ?Can LL-37/chitosan hydrogel be scaled up for clinical trials in human pressure ulcer patients?
- ?How does the release kinetics of LL-37 from chitosan compare to other hydrogel delivery systems?
- ?Would this approach work for other chronic wound types like diabetic ulcers or venous stasis wounds?
Trust & Context
- Key Stat:
- 48.12% remaining wound area at day 15 with LL-37/chitosan hydrogel (significantly less than all control groups)
- Evidence Grade:
- Preclinical animal study with well-designed controls and multiple outcome measures. Small group sizes but clear treatment effects.
- Study Age:
- Published in 2020. Antimicrobial peptide wound dressings continue to be developed with various delivery systems.
- Original Title:
- Chitosan hydrogel encapsulated with LL-37 peptide promotes deep tissue injury healing in a mouse model.
- Published In:
- Military Medical Research, 7(1), 20 (2020)
- Authors:
- Yang, Xu(2), Guo, Jing-Lin, Han, Jing(3), Si, Rui-Juan, Liu, Pan-Pan, Zhang, Zi-Rui, Wang, Ai-Min, Zhang, Ju
- Database ID:
- RPEP-05218
Evidence Hierarchy
Frequently Asked Questions
What is LL-37?
LL-37 is the only human cathelicidin antimicrobial peptide. It kills bacteria, promotes wound healing, and stimulates new blood vessel formation, making it ideal for wound care applications.
Why use chitosan hydrogel?
Chitosan is a natural, biocompatible material derived from shellfish that forms a protective gel. It stabilizes LL-37 (which normally breaks down quickly in wounds), provides sustained release, and has its own mild antimicrobial properties.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05218APA
Yang, Xu; Guo, Jing-Lin; Han, Jing; Si, Rui-Juan; Liu, Pan-Pan; Zhang, Zi-Rui; Wang, Ai-Min; Zhang, Ju. (2020). Chitosan hydrogel encapsulated with LL-37 peptide promotes deep tissue injury healing in a mouse model.. Military Medical Research, 7(1), 20. https://doi.org/10.1186/s40779-020-00249-5
MLA
Yang, Xu, et al. "Chitosan hydrogel encapsulated with LL-37 peptide promotes deep tissue injury healing in a mouse model.." Military Medical Research, 2020. https://doi.org/10.1186/s40779-020-00249-5
RethinkPeptides
RethinkPeptides Research Database. "Chitosan hydrogel encapsulated with LL-37 peptide promotes d..." RPEP-05218. Retrieved from https://rethinkpeptides.com/research/yang-2020-chitosan-hydrogel-encapsulated-with
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.